Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
Postoperative radiotherapy for supraglottic cancer on real-world data: can we reduce dose to lymph node levels?
In: Radiation Oncology, Jg. 18 (2023-02-22), Heft 1, S. 1-9
Online
academicJournal
Zugriff:
Purpose: To evaluate prognosis for reducing postoperative radiotherapy (PORT) dose to lymph node levels of supraglottic cancer (SC) on real-world data. Method and materials: Patients were derived from two cancer centers. In center 1, the involved nodal levels (high-risk levels, HRL) and the next level received a dose of 60.06 Gy/1.82 Gy per fraction, while the other uninvolved levels (low-risk levels, LRL) received 50.96 Gy/1.82 Gy per fraction. In center 2, all received 50 Gy/2 Gy per fraction. The rates of high-risk levels control (HRC), regional control (RC), overall survival (OS), progression-free survival (PFS) and distant metastasis-free survival (DMFS) were calculated by Kaplan–Meier method. Result: Totally, 124 patients were included (62 in center 1, 62 in center 2). Most patients (106, 85.5%) had a stage T3/N + tumor. The median follow-up was 45 months (range 1–163 months). There were no significant differences in terms of OS (p = 0.126), RC (p = 0.514), PFS (p = 0.195) and DMFS (p = 0.834). Most regional recurrences (4, 80%) occurred within three years of treatment, and all occurred within the target volumes. No regional failure occurred in HRL in center 1, while three (3/4) failures occurred in center 2. Dose reduction prescription to HRL led to a lower HRC rate (100% vs. 90.6%, p = 0.009). While the rates of LRL control (98.4%) were equal between the two centers. Conclusion: Compared with a standard dose, the reduced dose to involved nodal levels showed inferior regional control for PORT, while uninvolved nodal levels showed equal outcomes. A dose of 50 Gy for HRL may be an unfavorable treatment option for SC. [ABSTRACT FROM AUTHOR]
Titel: |
Postoperative radiotherapy for supraglottic cancer on real-world data: can we reduce dose to lymph node levels?
|
---|---|
Autor/in / Beteiligte Person: | Xu, Yi ; Wei, Yumei ; Wang, Jingbo ; Zhang, Jianghu ; Chen, Xuesong ; Wu, Runye ; Liu, Qingfeng ; Qu, Yuan ; Wang, Kai ; Huang, Xiaodong ; Luo, Jingwei ; Xu, Wei ; Zhang, Ye ; Yi, Junlin |
Link: | |
Zeitschrift: | Radiation Oncology, Jg. 18 (2023-02-22), Heft 1, S. 1-9 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 1748-717X (print) |
DOI: | 10.1186/s13014-023-02228-1 |
Schlagwort: |
|
Sonstiges: |
|